Opendata, web and dolomites

FILODIAG

Ultra-Fast Molecular Filovirus Diagnostics - Sofia ref.: 115844

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 FILODIAG project word cloud

Explore the words cloud of the FILODIAG project. It provides you a very rough idea of what is the project "FILODIAG" about.

urgent    physicians    rome    heated    ebd    stage    there    withdrawal    medical    virus    sierra    overcoming    tests    spread    drastically    guidance    emg    ultra    ease    inmi    evd    special    safely    assay    accurately    saliva    limit    time    usually    laboratory    diagnosis    standard    facilities    diagnostics    genome    instrument    disease    potentially    particles    limiting    accurate    fluids    gold    nurse    competence    rely    limited    molecular    sensitivity    leone    magnetic    synthetic    dna    suspected    pcr    15    conduct    rapid    tested    core    thoroughly    times    infected    crisis    patients    multiplexed    fast    ebola    laser    urine    conventional    preparation    filodiag    turn    12    nanoparticles    oligos    fever    centre    gna    africa    sequence    signs    invasive    biosafety    corresponding    mub    risk    care    tentative    reaction    copies    perform    specificity    binding    point    minutes    immuno    blood    infection    incoming    decisive    lack    heating    integrate    italy    decisions    resource    cooling    west    clinical    detecting    diagnostic   

Project "FILODIAG" data sheet

The following table provides information about the project.

Coordinator
GNA BIOSOLUTIONS GMBH 

Organization address
address: Am Klopferspitz 19
city: Martinsried
postcode: 82152
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website http://www.filodiag.eu
 Total cost 2˙260˙105 €
 EC max contribution 2˙260˙105 € (100%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2014-02-single-stage
 Funding Scheme IMI2-RIA
 Starting year 2015
 Duration (year-month-day) from 2015-02-01   to  2017-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GNA BIOSOLUTIONS GMBH DE (Martinsried) coordinator 1˙461˙750.00
2    ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI-ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO IT (ROMA) participant 404˙105.00
3    MENDELOVA UNIVERZITA V BRNE CZ (BRNO SEVER) participant 381˙750.00
4    EMERGENCY LIFE SUPPORT FOR CIVILIAN WAR VICTIMS ONG ONLUS IT (MILANO) participant 12˙500.00

Map

 Project objective

There is an urgent need for fast and accurate diagnostic tests in the current Ebola crisis. The rapid diagnosis of EVD during early and late stage of infection is a decisive step for risk assessment and for guidance to physicians to take the necessary decisions to limit the spread of the infection, and to safely nurse the infected patients. While fast and easy-to-use tests usually rely on immuno-diagnostic approaches, they typically lack high sensitivity and specificity. The gold standard for accurate diagnostics, (Real-Time) PCR, however, is limited in terms of processing time, high costs, and in most cases also in terms of ease of use and the need of special laboratory facilities.

The aim of this project is to provide an ultra-fast and accurate molecular diagnostic instrument that can perform a molecular Ebola test within 10-15 minutes. Patients, suspected of Ebola Virus Disease (EBD), due to fever and/or other clinical signs, could be rapidly and accurately tested at the Point-of-Care by withdrawal of blood, or less invasive fluids, such as saliva or urine.

The core technology of this proposal is based on laser-heated nanoparticles (Laser PCR), overcoming the time-limiting step of heating and cooling the reaction sample in conventional PCR allowing for drastically reduced turn-around times. The project partners (GNA, INMI, MUB, EMG) have the competence to integrate sample preparation with virus-binding magnetic particles, ultra-fast molecular diagnostics with Laser PCR, test the system in a biosafety level 4 laboratory in Rome, Italy, and thoroughly conduct field testing in a medical care centre in West Africa (Sierra Leone).

A tentative Ebola Laser PCR assay has already been set up, detecting 10 target copies of synthetic DNA oligos, corresponding to the Ebola genome sequence, in less than 12 minutes. The FILODIAG project will deliver a potentially multiplexed diagnostic system fast enough for point-of need testing of incoming patients at low-resource

 Deliverables

List of deliverables.
Final report Websites, patent fillings, videos etc. 2019-10-08 14:22:42
Patent application for nanomaghemite particles for virus model Websites, patent fillings, videos etc. 2019-05-30 17:11:07
Performance evaluation of each integration step of the test platform Documents, reports 2019-04-25 22:12:48
Patent application for nanomaghemite particles for Ebola Websites, patent fillings, videos etc. 2019-04-25 22:12:47
Providing one improved Pharos instrument Demonstrators, pilots, prototypes 2019-04-25 22:12:47
Higher process integration Websites, patent fillings, videos etc. 2019-04-25 22:12:47

Take a look to the deliverables list in detail:  detailed list of FILODIAG deliverables.

 Publications

year authors and title journal last update
List of publications.
2016 Rebuffo-Scheer et al.
Rapid detection of cDNA from Ebola virus isolate by Laser PCR
published pages: , ISSN: , DOI:
ECCMID 2016, Poster Presentation 3838 2019-05-15
2015 Krejcova et al.
Beads-based automatic pcr for detection of lentivirus with Ebola gp protein
published pages: , ISSN: , DOI:
Targeting Ebola Paris 2015, Poster Presentation 48 2019-05-15
2015 Kizek et al.
Ebola gp protein fragments and their basic characterisati on provided by mass spectrometry, spectroscopy, chromatogra phy and electrochemi stry
published pages: , ISSN: , DOI:
Targeting Ebola Paris 2015, Poster Presentation 45 2019-05-15
2015 Michalek P. et al.
The preparation and characterisation of lentivirus with Ebola gp protein
published pages: , ISSN: , DOI:
Targeting Ebola Paris 2015, Poster Presentation 60 2019-05-15
2017 Rebuffo-Scheer et al.
Rapid One-Step RT-Laser PCR® detection of Ebola Virus: analytical performance evaluation and comparison with the commercially available RT-PCR kit RealStar® FilovirusScreen
published pages: , ISSN: , DOI:
ESCV 2017, poster presentation 2019-04-25
2017 INMI
TEST diagnostico per EBOLA: ricercatori INMI in missione in Sierra Leone
published pages: , ISSN: , DOI:
INMI Spallanzani Informa 2019-04-25
2018 INMI
Validazione di un nuovo test Diagnostico: “Ebola, ricercatori dello Spallanzani”
published pages: , ISSN: , DOI:
La Sanità del Lazio N°16, March 2018 2019-04-25

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FILODIAG" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FILODIAG" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

RespiriNTM (2019)

Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs

Read More  

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More  

RespiriTB (2019)

Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors

Read More